ANDA 76967, held by Hikma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 76967 (Ondansetron Hydrochloride), held by Hikma, was first approved by FDA on Dec 26, 2006, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Apr 3, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 3, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 30, 2010 | Supplement 2Labeling | Approved | None posted |
| Jan 28, 2010 | Supplement 1Labeling | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters